BACKGROUND: Pattern and outcome of disease recurrence after autologous stem-cell transplantation (autoSCT) for follicular lymphoma (FL) is not well known. PATIENTS AND METHODS: Relapse cases were identified from 241 consecutive patients autografted for disseminated untransformed FL from 1990 to 2002 in three institutions. Prognostic factors for relapse and outcome after relapse were analyzed by log-rank comparisons and Cox regression analyses. RESULTS: One hundred and three relapses occurred. The 10-year relapse probability was 47%. Median time from autoSCT to relapse was 20 (2-128) months. Only three relapses were observed later than 6 years posttransplant. Median survival after relapse was 8.3 years. Patients with disease recurrence within 1 year from transplant and those who had received autoSCT as second-line treatment had significantly reduced survival by multivariate analysis, whereas Follicular Lymphoma International Prognostic Index score, age, remission status at autoSCT, high-dose regimen, and ex vivo purging had no impact. CONCLUSIONS: FL recurrence after autoSCT follows a biphasic pattern with continuing relapse during the first 6 years and only few events thereafter. The prognosis after relapse is relatively good and appears to be comparable to that of disease recurrence after standard treatment. The situation is less favorable for patients who relapse within the first posttransplant year.
BACKGROUND: Pattern and outcome of disease recurrence after autologous stem-cell transplantation (autoSCT) for follicular lymphoma (FL) is not well known. PATIENTS AND METHODS: Relapse cases were identified from 241 consecutive patients autografted for disseminated untransformed FL from 1990 to 2002 in three institutions. Prognostic factors for relapse and outcome after relapse were analyzed by log-rank comparisons and Cox regression analyses. RESULTS: One hundred and three relapses occurred. The 10-year relapse probability was 47%. Median time from autoSCT to relapse was 20 (2-128) months. Only three relapses were observed later than 6 years posttransplant. Median survival after relapse was 8.3 years. Patients with disease recurrence within 1 year from transplant and those who had received autoSCT as second-line treatment had significantly reduced survival by multivariate analysis, whereas Follicular Lymphoma International Prognostic Index score, age, remission status at autoSCT, high-dose regimen, and ex vivo purging had no impact. CONCLUSIONS: FL recurrence after autoSCT follows a biphasic pattern with continuing relapse during the first 6 years and only few events thereafter. The prognosis after relapse is relatively good and appears to be comparable to that of disease recurrence after standard treatment. The situation is less favorable for patients who relapse within the first posttransplant year.
Authors: Silvia Montoto; Janet Matthews; Paul Greaves; Debra Lillington; Deborah Anderson; John G Gribben; T Andrew Lister Journal: Haematologica Date: 2012-11-09 Impact factor: 9.941
Authors: Yvette L Kasamon; Richard J Jones; Christopher D Gocke; Amanda L Blackford; Eric J Seifter; Janice M Davis-Sproul; Steven D Gore; Richard F Ambinder Journal: Biol Blood Marrow Transplant Date: 2010-07-22 Impact factor: 5.742
Authors: Matthew A Lunning; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Hugo Castro-Malaspina; Sergio Giralt; Miguel-Angel Perales; Andrew D Zelenetz; Craig H Moskowitz; Craig S Sauter Journal: Br J Haematol Date: 2016-02-05 Impact factor: 6.998
Authors: Grzegorz Helbig; Malgorzata Krawczyk-Kulis; Anna Kopinska; Robert Liwoch; Slawomira Kyrcz-Krzemien Journal: Med Oncol Date: 2014-11-06 Impact factor: 3.064
Authors: Ana Jiménez-Ubieto; Carlos Grande; Dolores Caballero; Lucrecia Yáñez; Silvana Novelli; Miguel T Hernández; María Manzanares; Reyes Arranz; José Javier Ferreiro; Sabela Bobillo; Santiago Mercadal; Andrea Galego; Javier López Jiménez; José María Moraleda; Carlos Vallejo; Carmen Albo; Elena Pérez; Carmen Marrero; Laura Magnano; Luis Palomera; Isidro Jarque; Erika Coria; Antonia Rodriguez; Alejandro Martín; Armando López-Guillermo; Antonio Salar; Juan José Lahuerta Journal: Cancer Med Date: 2017-10-26 Impact factor: 4.452